APA (7th ed.) Citation

MS, R., N, W., KM, K., J, K., R, F., K, W., . . . L, R. (2026). Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: A phase 2 trial. Nature medicine, 32(7), 2440. https://doi.org/10.1038/s41591-026-04471-x

Chicago Style (17th ed.) Citation

MS, Raab, et al. "Teclistamab-based Induction Treatment in Transplant-eligible, Newly Diagnosed Multiple Myeloma: A Phase 2 Trial." Nature Medicine 32, no. 7 (2026): 2440. https://doi.org/10.1038/s41591-026-04471-x.

MLA (9th ed.) Citation

MS, Raab, et al. "Teclistamab-based Induction Treatment in Transplant-eligible, Newly Diagnosed Multiple Myeloma: A Phase 2 Trial." Nature Medicine, vol. 32, no. 7, 2026, p. 2440, https://doi.org/10.1038/s41591-026-04471-x.